News & Updates
Filter by Specialty:
Pandemic-related delays in thrombolysis worsens outcomes
Patients who have had to delay their intravenous thrombolysis (IVT) procedures due to the COVID-19 pandemic suffer from worse short-term clinical outcomes such as higher rates of mortality and hospice care, reports a study presented at the Annual Meeting of the American Academy of Neurology (AAN 2022). These patients are also less likely to be discharged to their homes or to rehabilitation facilities.
Pandemic-related delays in thrombolysis worsens outcomes
25 Apr 2022Renal denervation aids in long-term blood pressure control
Patients with uncontrolled hypertension can benefit from renal sympathetic denervation, which leads to notable reductions in systolic blood pressure (SBP) after 6 months of intervention, reports the proof-of-concept SPYRAL HTN-ON MED trial presented at ACC.22.
Renal denervation aids in long-term blood pressure control
25 Apr 2022Obesity modifies link between menopausal age and heart failure risk
The risk of developing heart failure appears to increase in proportion with the level of obesity, especially among women whose menopause occurred at ≥55 years of age, a study has found.
Obesity modifies link between menopausal age and heart failure risk
25 Apr 2022Left atrial measures predict heart failure in older adults
Novel measures of left atrial (LA) structure and function, but not standard assessment by LA maximal (LAViMax), appear to be prognostic of a higher risk of incident heart failure (HF) or death, irrespective of measures of left ventricular function and N-terminal pro‒B-type natriuretic-peptide (NT-proBNP), suggests a recent study.
Left atrial measures predict heart failure in older adults
24 Apr 2022Once- on par with twice-daily cilostazol–Ginkgo biloba combo in peripheral arterial disease
In the treatment of ischemic symptoms associated with peripheral arterial disease, the use of once-daily SID142 appears to be as good as twice-daily Renexin while having a favourable safety profile, as shown in a phase III study.